Beijing Konruns Pharmaceutical Co., Ltd (SHA: 603590) announced that China’s National Medical Products Administration (NMPA) has approved clinical trials for KC1036, its Class 1 innovative small‑molecule drug, in combination with PD‑1/PD‑L1 therapies for recurrent or metastatic advanced solid tumors. The dual‑target inhibitor (VEGFR2 + AXL) aims to enhance immunotherapy efficacy through vascular normalization and immune response improvement.
Enhanced immunotherapy efficacy via vascular normalization + immune activation
Strategic Implications
IO Combination Rationale: The PD‑1/PD‑L1 combination strategy addresses primary resistance to immunotherapy in “cold” tumors; KC1036’s VEGFR2/AXL inhibition converts immune‑excluded microenvironments to immune‑permissive states, potentially expanding IO responder populations.
AXL Differentiation: While VEGFR inhibitors (sunitinib, axitinib) are established, AXL targeting is novel in IO combinations; AXL drives tumor cell migration, immune suppression, and therapy resistance—blockade may sensitize resistant tumors to checkpoint inhibitors.
Global IP Position:Full global intellectual property rights enable unencumbered worldwide development and out‑licensing flexibility, positioning Konruns for multinational partnership or independent US/EU regulatory submissions.
Solid Tumor Breadth: The advanced solid tumor indication—spanning lung, liver, gastric, and other malignancies—provides basket trial flexibility to identify responsive tumor types and biomarker‑selected populations.
Market Context
Factor
Impact
IO Combination Market
~ $50 billion globally; VEGF/VEGFR inhibitors + PD‑1 standard in renal cell carcinoma, hepatocellular carcinoma; AXL addition represents next‑gen approach
AXL Inhibitor Landscape
Berzosertib (Merck KGaA), bemcentinib (BerGenBio) in development; KC1036’s dual VEGFR2/AXL profile may offer superior efficacy vs. single‑target AXL inhibitors
Forward‑Looking Statements This brief contains forward‑looking statements regarding Phase I/II enrollment, IO combination safety, and efficacy outcomes for KC1036. Actual results may differ due to risks including additive toxicity with PD‑1 inhibitors, competitive VEGFR/AXL program advancement, and biomarker selection complexity.-Fineline Info & Tech
By Fineline Cube